Yousif Capital Management LLC Sells 7,493 Shares of Abbott Laboratories $ABT

Yousif Capital Management LLC lowered its position in Abbott Laboratories (NYSE:ABT) by 3.0% in the 4th quarter, Holdings Channel reports. The firm owned 245,079 shares of the healthcare product maker’s stock after selling 7,493 shares during the quarter. Yousif Capital Management LLC’s holdings in Abbott Laboratories were worth $29,689,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in ABT. Harbor Capital Advisors Inc. bought a new stake in Abbott Laboratories in the fourth quarter worth about $27,000. Cloud Capital Management LLC bought a new stake in Abbott Laboratories in the third quarter worth about $29,000. Guerra Advisors Inc purchased a new position in shares of Abbott Laboratories during the third quarter worth approximately $31,000. Delos Wealth Advisors LLC purchased a new position in shares of Abbott Laboratories during the second quarter worth approximately $32,000. Finally, Bridge Generations Wealth Management LLC purchased a new position in shares of Abbott Laboratories during the third quarter worth approximately $33,000. Institutional investors own 75.18% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Citigroup reduced their target price on shares of Abbott Laboratories from $140.00 to $136.00 and set a “buy” rating on the stock in a research report on Wednesday, March 11th. Leerink Partners reduced their target price on shares of Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating on the stock in a research report on Friday, January 30th. BTIG Research reduced their target price on shares of Abbott Laboratories from $140.00 to $131.00 and set a “buy” rating on the stock in a research report on Tuesday, March 31st. Royal Bank Of Canada reduced their target price on shares of Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Finally, Weiss Ratings lowered shares of Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, January 26th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, Abbott Laboratories currently has an average rating of “Moderate Buy” and an average price target of $135.47.

Insider Buying and Selling

In other Abbott Laboratories news, SVP Eric Shroff sold 709 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $81,946.22. Following the completion of the sale, the senior vice president directly owned 39,164 shares in the company, valued at $4,526,575.12. This trade represents a 1.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Elizabeth C. Cushman sold 263 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $30,397.54. Following the completion of the sale, the executive vice president owned 38,573 shares of the company’s stock, valued at approximately $4,458,267.34. This trade represents a 0.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 3,055 shares of company stock valued at $353,097 over the last quarter. Insiders own 0.46% of the company’s stock.

Abbott Laboratories Stock Performance

Shares of ABT stock opened at $101.77 on Wednesday. The firm has a market cap of $177.25 billion, a price-to-earnings ratio of 27.36, a PEG ratio of 1.64 and a beta of 0.79. The company’s 50 day moving average is $109.22 and its 200 day moving average is $120.47. The company has a quick ratio of 1.18, a current ratio of 1.58 and a debt-to-equity ratio of 0.19. Abbott Laboratories has a 52-week low of $100.88 and a 52-week high of $139.06.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.50. The company had revenue of $11.46 billion for the quarter, compared to analyst estimates of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. Abbott Laboratories’s revenue was up 4.4% compared to the same quarter last year. During the same period last year, the company posted $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, sell-side analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 2.5%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio (DPR) is 67.74%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.